Chromosomal microarray analysis (CMA) has improved the diagnostic rate of genomic disorders in pediatric populations, but can produce uncertain and unexpected findings. This article explores clinicians' perspectives and identifies challenges in effectively interpreting results and communicating with families about CMA. Responses to an online survey were obtained from 40 clinicians who had ordered CMA. Content included practice characteristics and perceptions, and queries about a hypothetical case involving uncertain and incidental findings. Data were analyzed using nonparametric statistical tests. Clinicians' comfort levels differed significantly for explaining uncertain, abnormal, and normal CMA results, with lowest levels for uncertain results. Despite clinical guidelines recommending informed consent, many clinicians did not consider it pertinent to discuss the potential for CMA to reveal information concerning biological parentage or predisposition to late-onset disease, in a hypothetical case. Many non-genetics professionals ordering CMA did not feel equipped to interpret the results for patients, and articulated needs for education and access to genetics professionals. This exploratory study highlights key challenges in the practice of genomic medicine, and identifies needs for education, disseminated practice guidelines, and access to genetics professionals, especially when dealing with uncertain or unexpected findings.
significance (VUS), incidental findings (IFs), and the implications of CMA results for relatives (2) (3) (4) (5) (6) .
Clinicians ordering cytogenomic testing have an important role in preparing families for testing and communicating results. Guidelines specific to CMA emphasize the importance of pre-test counseling and informed consent to ensure that families are prepared for the information, and make an informed decision about how much information to receive (1, 2, 4, (7) (8) (9) . Initial guidelines suggest informing patients of the potential for unexpected findings, which should be reported with consideration of clinical relevance as well as social, ethical and legal issues. For a VUS, some guidelines recommend genetic consultation, genetic counseling, or both, and monitoring of the medical literature by the physician with an ongoing patient relationship (8) . The American Academy of Pediatrics recommendations for genetic testing predate the clinical use of CMA, but are still relevant. They recommend informed consent for genetic tests, provision of information to parents about potential treatment of disorders detected in their child, discussion of potential harms in gaining genetic information, and collaboration among pediatricians and genetics professionals (10, 11) .
We believe that it is important to understand the perspectives of physicians using CMA in their clinical practice, to identify practices that may correspond with or deviate from current guidelines, to understand reasons for diverging practices, and to identify specific challenges in ordering, interpreting and conveying CMA results. Our study explores current practices and considerations pertaining to CMA testing among a group of physicians who have ordered CMA testing for pediatric patients. This article focuses on physicians' responses to uncertain and incidental findings of CMA, and their views on reporting and communicating these findings. The ethical and psychosocial concerns raised by CMA technology reflect issues that will apply on a larger scale to whole genome sequencing and other clinical applications of genomics (12) .
Materials and methods
The results described here represent one component of an exploratory study of the impact of CMA testing on families and health providers of pediatric outpatients. The study included interviews, observations and a survey involving families and providers. A previous paper reported findings pertaining to parents' understandings of CMA results (13) .
Sample
Physicians who ordered CMA testing at least once through the Cytogenomics Laboratory at the Children's Hospital of Philadelphia between May 2008 and March 2011 were sent emails inviting their participation in an anonymous online survey, for which a link was provided. Surveys were completed between March and May 2011.
Emails were sent to 324 physicians, and 51 (16%) responded, of whom 40 were included in the analysis for this article. Response rates were 21% for pediatricians, 26% for geneticists, and 11% for specialists. As we were interested only in physicians with patient contact in the pediatric setting, we excluded three pathologists and one obstetrician/gynecologist. We also excluded seven respondents who failed to provide responses for most items analyzed in this article. Some items had missing responses, and sample sizes for these are noted in the tables (n = 37 is the lowest).
The study was approved by the Institutional Review Board at the Children's Hospital of Philadelphia.
Instrument
The survey was informed by preliminary qualitative analysis of interviews and clinical observations involving health professionals and families of children undergoing CMA testing (13) . Items about genetics training and knowledge were based on a national survey of physicians' utilization of genetic testing (14) . The online survey comprised 50 items, divided into seven sections: (i) demographics; (ii) medical practice characteristics and training in genetics; (iii) education and general experience with CMA testing; (iv) an evolving hypothetical scenario (see Table 2 for specific items); (v) level of comfort interpreting and explaining CMA results; (vi) impact of CMA testing on clinical practice; and (vii) personality characteristics.
This article focuses on physicians' experience and perceptions regarding CMA, and their responses to the evolving scenario. Responses were measured for some items by 6-point Likert scales, and for others by selection of pre-determined responses. Several questions included open-text options for additional responses and clarification.
Data analysis
Statistical analyses were performed using spss and sas software. Wilcoxon signed rank tests were used for paired comparisons between responses to varying hypothetical situations in the scenario (e.g. likelihood of disclosing a genetic predisposition to Alzheimer disease as compared to colon cancer). Friedman's tests were similarly used for the repeated measures on comfort levels when explaining the three different types of results (VUS, normal, and abnormal). For all the three-way comparisons among the independent medical specialties, Kruskal-Wallis tests were used for the Likert scales, and Fisher's exact tests for dichotomous outcomes.
Open-text responses were categorized according to themes by two independent coders (M. R. and K. R.). Discrepancies were resolved by discussion, and the frequency of respondents reporting each theme was calculated.
Results

Sample characteristics and experience with CMA testing
Respondents included physicians from three medical specialty groups: general pediatrics (27.5%), medical genetics (12.5%), and pediatric subspecialties (60%; including seven neonatologists, five neurologists, four pediatric endocrinologists, three developmental pediatricians, one hematologist, one gastroenterologist, one oncologist, one ophthalmologist, and one critical care specialist). Sample characteristics are presented in Table 1 . Comfort levels differed for explaining the three types of results (normal, abnormal, and VUS), with lowest comfort levels for VUS results (Table 1) .
Responses to evolving hypothetical scenario
Most physicians were likely to offer the CMA test for a hypothetical patient (mean 4.14 ± 1.66 on a 6-point scale) ( Table 2 ). Upon receiving a VUS result, most respondents (70%) indicated that they would disclose to parents 'the location and approximate size of the deletion, and that the findings were inconclusive'. Several non-geneticists added (in open text) that they would explain the meaning of the finding and refer for a medical genetics consultation if the parents had further questions.
Pre-test preparation for parental testing
Prior to parental testing, 59% of physicians considered it pertinent to discuss the potential for an unexpected finding of a predisposition to certain diseases. Thirty percent of respondents thought it pertinent to discuss the potential for findings regarding biological parentage, and 10% were unsure what to discuss.
Implications of a VUS result for relatives
Opinions were divided regarding the likelihood of recommending testing for a relative following a VUS finding. Open-text responses (provided by 21 respondents) revealed that some physicians thought that an inconclusive result was not meaningful, and therefore there was no reason to test the patient's relative, while others thought that testing could help to inform reproductive decisions, or to facilitate finding a diagnosis. Respondents articulated that their decision would be guided by the specific nature of the findings, family preferences, and ethical considerations: some suggested that contingencies (such as variable penetrance, an X-linked condition, the genes in the deleted region) were relevant to their decision, and several stated that it was the family's decision.
Response to an incidental finding
Physicians were asked about their preferences for reporting an IF in the maternal array test associated with a predisposition to develop Alzheimer disease. While about 60% of respondents preferred full disclosure of IFs in the laboratory report, the remaining 40% chose other options: to be informed verbally; not to be informed at all; to leave it to the laboratory's discretion; or were unsure. One respondent noted that laboratories appear to differ in what they report.
Physicians rated colon cancer as more actionable than Alzheimer disease (p < 0.0001), and were more likely to disclose a genetic predisposition to colon cancer vs Alzhiemer disease (p < 0.0001). Thirty percent of respondents were likely (scored ≥4) to suggest that a parent inform her sibs of a predisposition to Alzheimer disease. 
Comparison among medical specialties
All the medical geneticists reported ordering more than 30 cytogenomic arrays, compared with 37.5% of the pediatric sub-specialists, and none of the general pediatricians. Perceived need for more education about interpreting and explaining results was highest for pediatricians, followed by pediatric sub-specialists and medical geneticists, and the differences among the three means were significant (respective means were 5.0 ± 1.3, 4.0 ± 1.6, and 2.0 ± 1.2; p = 0.006). Ratings of parents' understanding differed among the three specialty groups; means were 4.0 ± 1.4 for geneticists, 2.2 ± 1.1 for pediatricians and 2.3 ± 0.8 for subspecialists (p = 0.027). Most non-geneticists (82% of pediatricians and 62% of pediatric sub-specialists) reported that they would discuss a VUS finding with a genetic specialist. All of the general pediatricians considered it pertinent to discuss the potential for an IF prior to testing a parent, while only 39% of the pediatric sub-specialists and 60% of medical geneticists agreed (p < 0.001).
Pediatricians also tended to prefer full disclosure of a predisposition to Alzheimer disease (70% of pediatricians, 59% of specialists, and 40% of geneticists), and to be more likely to recommend informing relatives of an IF (46% of pediatricians, 25% of specialists and 20% of geneticists scored ≥4 on a 6-point scale), although these differences were not considered statistically significant.
Discussion
The results of this exploratory study provide insight into the ways physicians are managing genomic medicine and elucidate some key challenges regarding uncertain and incidental findings, with implications for pre-and post-test counseling and provider education.
Pre-test counseling
An important finding of this study was the variety of opinions regarding appropriate information to convey before parental testing. Forty-one percent of respondents did not consider it pertinent to discuss the potential for IFs. If parents are told only that the test will determine whether the child's deletion/duplication is also present in a parent, they may not be aware of the full scope of potential results. While there are no formal requirements for informed consent for CMA, clinical guidelines recommend that patients and families should be informed of the potential for IFs (2, 4, 7, 8) . Our study suggests some discrepancies between clinical practice (as reported regarding a hypothetical situation) and recommended practice with respect to pre-test counseling about IFs.
Physicians may not be inclined to discuss the potential for IFs for several reasons: in the context of CMA, IFs are rare, seen in only 1% of the population tested (15) ; and discussion of such findings may be anxiety-provoking and time-consuming. Given the vast number of possibilities, it is not feasible to discuss options for reporting each potential finding (16, 17) , but it is also inappropriate to present the choice of whether to be informed only after detecting a deleterious variant (3). A 'generic consent' option (18) could provide information about general categories rather than specific outcomes, and some suggest that pre-test discussions review possible IFs in terms of age of onset, severity, treatability and prevention, and consider interests of children, parents and other relatives (17) .
Post-test counseling
Disclosing incidental findings
The differing opinions articulated by respondents regarding disclosure of IFs echo recognized controversies. While clinicians have a responsibility to inform patients of clinically meaningful IFs, such results in a healthy individual may lead to unnecessary and expensive interventions (19, 20) . In addition, genetic testing has been found to benefit patients and their relatives (21) and facilitate preventative interventions, but adverse psychological responses have been reported in some individuals and concerns about privacy and confidentiality often intervene (11, 21, 22) . We cannot assume that everyone would want to be informed of an IF, even if medically actionable, as shown by findings that many people from families with adult-onset genetic disorders (e.g. Huntington disease, hereditary breast cancer, HNPCC-colon cancer, hereditary hemorrhagic telangiectasia, Alzheimer disease) choose not to have genetic testing (11, (23) (24) (25) . An added complication of CMA is that parental testing increases the complexity and quantity of genetic data generated, and the findings may be beyond the expertise of the ordering physician.
Our finding that physicians were more likely to disclose a genetic propensity for a medically actionable disease (colon cancer) compared with one that is currently less actionable (Alzheimer disease) is consistent with the approach in genetic research, where treatability and clinical utility guide disclosure decisions (26) (27) (28) . Berg and colleagues (16) suggest that clinically actionable IFs should always be reported, while reporting of clinically valid but not directly actionable variants (e.g. alleles associated with Alzheimer disease) should be based on patient preference. Confounding these issues is the current indecision among genetics professionals as to which IFs to report (29) . If patients' wishes are unclear, or laboratorians feel uncomfortable not reporting IFs, decisions about reporting and counseling should be made in collaboration with clinicians familiar with the clinical and social situation of the family, weighing harms and benefits of the information.
Uncertain findings
Our finding that physicians' levels of comfort explaining results to families were lowest for VUS results was consistent with other reports, (3, 4, 30) and possibly attributable to health physicians' general discomfort with uncertain results of genetic tests (31, 32) .
With whole-genome sequencing, VUS results will increase dramatically (12) . Berg and colleagues (16) suggest that variants of no known clinical significance (i.e. not linked to a phenotype, clinical outcome or intervention) not be included in the primary clinical record or discussed with patients. While this approach may be helpful in managing the quantity of VUS results, the issue will continue to be challenging because it is customary to disclose findings of genetic testing according to preferences of the family, and families may wish to know about all VUS results (3). In addition, some VUS results will later be classified as deleterious, and awareness of the result and its reinterpretation would, in theory, permit a clinician to update a patient. However, this 'duty to re-contact' is fraught with logistic, economic and legal considerations (33) . We recommend counseling the patient or parents that much remains to be learned and that, if interested, they should re-contact their physician in the future to learn if new information is available.
Implications for relatives
The diversity of opinion in our study regarding testing relatives reflects ethical dilemmas concerning the duty to inform relatives and the patient's right to privacy (21, (34) (35) (36) (37) (38) (39) . The physicians in our sample tended to assess the specific genetic findings, medical risk, and implications for reproductive decisions in the context of the personal preferences and family relationships of the individuals tested, suggesting a complex decisionmaking process that appears consistent with a shared decision model (40) .
CMA and non-genetics providers
Our findings that pediatricians and pediatric specialists reported a need for more education about CMA are consistent with reports that non-genetics medical professionals lack the confidence, knowledge and communication skills required for effective genetic counseling (41) (42) (43) . Lower ratings of parents' understanding by non-geneticists than by geneticists concurs with findings that parents' understanding can be impeded by receiving results from providers lacking genetics expertise, and improved by consultations with genetics professionals (13) . Our finding that, on receiving a VUS result, non-genetics clinicians are likely to consult with and/or refer to a geneticist, highlights the recognized need for patients and providers to have timely access to genetics professional, especially as genetic information becomes increasingly available (12) . However, the current medical genetics workforce is not sufficient to manage the demand for their services (7, 44) . Non-geneticist clinicians are playing an increasing role in genomic medicine, and they require additional genetics training (11, 41, (43) (44) (45) (46) (47) . Our data support the view that educational resources need to be developed for non-genetics providers to facilitate their interpretation of CMA results and counseling of families (2).
Limitations
While our study provides valuable insights into some key issues faced by physicians ordering CMA, there are several limitations: like many other surveys of physicians, our response rate was low (47) , and those who participated are likely to have greater interest in the topic; respondents were associated with a laboratory at a university-affiliated hospital, therefore findings are not generalizable to physicians in communitybased practices; hypothetical scenarios may not mirror how physicians might respond to actual patients; and sample size is insufficient to control statistically for demographic and interaction effects.
Despite the limitations, our findings contribute to our understanding of how health professionals incorporate new genetic technologies. This is the first study we know of to describe the ways in which providers are likely to act with respect to ordering CMA and discussing results with patients and families. Even in this relatively small sample of physicians there is little consensus about important issues regarding managing IFs. Our findings are helpful in identifying needs of providers for educational interventions addressing pre-and post-test counseling regarding uncertain and unexpected results.
Recommendations for future research and practice
A larger survey is needed to assess the opinions of a wider range of clinicians and to gain deeper insights into their perspectives. Future studies need to explore ethical and psychosocial issues raised by CMA, the best ways to address IFs in clinical practice, and the reasons underlying providers' divergent opinions about communicating the potential for IFs. The evaluation of new genomic tests should be accompanied by research on informed consent procedures and on the implications of incidental and uncertain findings for patients and relatives. Interventions need to be developed to train providers in interpreting and conveying CMA results, and it is important to elicit perspectives of patients and families as well as providers regarding informed consent and communication of results. Guidelines need to be updated and disseminated to non-geneticists ordering CMA.
Collaboration between geneticists, clinical laboratories, and other health care specialists needs to be facilitated in order to support providers and families, including assistance with interpretation of results and monitoring research for new information about VUS results. Clearly, considerations about IFs (which IFs are medically actionable, at what age to report, should all be included in the medical record, etc.) will evolve over time as a variety of research consortia grapple with these issues.
Conclusions
CMA is a new technology presenting challenges to providers with respect to uncertain and incidental findings. Our study explored perspectives of providers using the test, and can be used to gauge likely early reactions and needs with respect to whole genome sequencing. While recommendations and guidelines for genetic testing suggest providing pre-test information to prepare families for IFs, a sizable proportion of clinicians did not consider it pertinent to explain the potential for IFs. We identified needs for education and access to guidelines, especially in the presence of uncertain or unexpected findings.
